Background Whether people living with HIV who have not received antiretroviral therapy (ART) and have high CD4 cell counts have higher mortality than the general population is unknown. We aimed to examine this by analysis of pooled data from industrialised countries.
Introduction
In people infected with HIV, risk of death increases as CD4 cell count declines, 1 and this trend has been noted even in the high CD4 count range. 2, 3 Risk of death not attributable to AIDS is associated with CD4 cell count, although not as strongly as for AIDS deaths. 4 The optimum CD4 cell count at which to start antiretroviral therapy (ART) in individuals infected with HIV is unclear. Most guidelines state that, in patients without a previous AIDS event, ART should be started when the CD4 count falls to 350 cells per μL. 5, 6 Evidence as to whether starting ART at greater CD4 cell counts might be benefi cial is restricted to observational studies, 7, 8 and to a subanalysis of the SMART trial. 9 Observational studies have attempted to mimic the comparison made in randomised trials, comparing outcomes from immediate versus deferred ART initiation, and have generally concluded that earlier initiation will probably lead to lower risk of death, although results are inconsistent. 7, 8 We sought to use observational data to address a more fundamental question about the potential benefi t of early introduction of ART: are ART-naive patients with CD4 count greater than 350 cells per μL at higher risk of death than the general population?
We compared mortality in a large multinational collaborative cohort study of people with HIV with that expected for the general population, standardised by age, sex, country, and year. Furthermore, we considered whether death rates in these patients diff ered with CD4 cell count.
Methods

Data collection
23 cohorts and cohort collaborations contributed data for this analysis. 18 cohorts were based in Europe and fi ve in North America. Data were requested in a standard format, 10 and duplicate records were removed where patients were in more than one cohort. Data requested from participating cohorts included demographic information, CD4 cell counts, viral-load measurements, hepatitis C co-infection status, smoking status, date of death, and whether death was AIDS-related or not. This analysis was restricted to patients aged 20-59 years who had at least one CD4 count greater than 350 cells per μL while ART naive. All pre-ART CD4 counts greater than 350 cells per μL from January, 1990, to December, 2004, were included. The exclusion of CD4 cell counts after 2004 was to mitigate the eff ect of any delay in reporting of deaths. All CD4 cell counts measured during prospective follow-up were included-ie, after enrolment to a cohort while ART naive.
Statistical analysis
For each patient, the follow-up included was from the date of each eligible CD4 cell count until the earliest of next count, death, start of ART, or elapse of 1 year (fi gure 1). Standardised mortality ratios (SMRs) were calculated by comparing observed death rates with those expected in the general population, standardised by age, sex, country, and year of CD4 cell count. The data used for calculation of the SMRs were restricted to those countries for which mortality data for the general population were available from the Human Mortality Database (University of California, Berkeley, and Max Planck Institute for Demographic Research; accessed May 20, 2009), and for which there was at least 2000 person-years of follow-up.
Poisson regression methods were used to investigate the relation between death rate and CD4 cell count. Other factors included in the multivariate model were sex, risk group, age, current calendar year, and most recent viralload measurement (no earlier than 6 months before the date of the included CD4 cell count). Hepatitis C co-infection and smoking status were also included as factors in models restricted to data from cohorts able to provide such data.
Three sensitivity analyses were done. In the fi rst, follow-up was censored at 6 months after each CD4 cell count instead of at 1 year, to test the assumption implicit in the main analysis that the most recent CD4 cell count was valid for up to 1 year. In the second, the main analysis was repeated but only follow-up after CD4 counts greater than 500 cells per μL was included, to establish whether there was a raised risk of death in this higher CD4 cell count range. In the third, to assess the eff ect of any possible underascertainment of deaths, the SMRs were calculated by use of data from only those cohorts that are known to be linked to national death registers.
All p values are two-sided. Analyses were done with SAS version 9.1 (Cary, NC, USA).
Role of the funding source
The study sponsors had no role in the study design, analysis, interpretation of data, writing of the report, or in the decision to submit the paper for publication. Final responsibility for the decision to submit for publication was held by the Analysis and Writing Committee. 
Risk group
Men who have sex with men 39 732 49·2% 419 (1·0%) patients died during follow-up, giving an overall mortality of 5·2 per 1000 person-years (95% CI 4·7-5·7). Of these, 61 (15%) deaths were categorised as AIDS-related, 188 (45%) were categorised as non-AIDSrelated, and the cause was unknown for 170 deaths (41%).
The SMR analysis for pre-ART CD4 counts greater than 350 cells per μL included 38 997 patients (95·5% of the total: the SMR analysis was restricted to those countries for which data were available from the Human Mortality Database, and for which there were at least 2000 personyears of follow-up), with 77 936 person-years of follow-up (96·6% of the total) and 401 deaths (96% of the total). Table 2 shows the observed death rates and SMRs standardised by age, sex, country, and year for each risk group. SMR was lowest in men who have sex with men and highest among injecting drug users. When the analysis was restricted to CD4 counts greater than 500 cells per μL, the resulting SMRs were slightly lower at 2·83 (95% CI 2·03-3·87) for the heterosexual risk group, 7·97 (95% CI 6·55-9·60) for injecting drug users, and 4·47 (95% CI 2·61-7·16) for the other or unknown risk group. For men who have sex with men, however, the SMR was 1·03 (95% CI 0·76-1·37). For CD4 counts greater than 350 cells per μL but with follow-up censored at 6 months after each CD4 cell count instead of at 1 year, the SMRs were slightly lower than in the main analysis at 1·14 (95% CI 0·90-1·43) for homosexual men, 2·74 (95% CI 2·05-3·60) for the heterosexual risk group, 9·35 (95% CI 7·93-10·94) for injecting drug users, and 3·30 (95% CI 1·96-5·22) for the other or unknown risk group. Restriction of the analysis to follow-up from patients within cohorts linked to national death registers resulted in slightly higher SMRs than in the main analysis, at 1·52 (95% CI 1·10-2·04) for men who have sex with men, 3·29 (95% CI 2·09-4·94) for the heterosexual risk group, 15·85 (95% CI 11·27-21·67) for injecting drug users, and 6·99 (95% CI 3·99-11·35) for the other or unknown risk group.
In a Poisson regression model fi tted to the full dataset, a CD4 count greater than 500 cells per μL was associated with a lower risk of death than CD4 count between 350 cells per μL and 499 cells per μL (fi gure 2). The unadjusted risk ratios were 0·75 (95% CI 0·60-0·93) for CD4 counts of 500-699 cells per μL and 0·67 (95% CI 0·52-0·86) for counts of 700 cells per μL or greater, compared with 350-499 cells per μL (table 3) . Signifi cant predictors of death in univariate analyses were risk group and age. Sex and calendar year of CD4 cell count were not associated with the rate of death in univariate analyses, but were signifi cant factors in the multivariate model. Viral load, which was available for only 60·1% of total follow-up, was not associated with death rate. After adjustment for the other factors in the model, the rate ratios for the CD4 cell count remained largely unchanged at 0·77 (95% CI 0·61-0·95) for counts of 500-699 cells per μL and 0·66 (95% CI 0·52-0·85) for counts of 700 cells per μL or greater, compared with 350-499 cells per μL. 350-499 500-699 ≥700 In the two models fi tted to subsets of the data to include hepatitis C and smoking covariates respectively, the associations between CD4 cell count and death rate were consistent with those in the main model.
In a sensitivity analysis with follow-up censored at 6 months after each CD4 cell count instead of at 1 year, the association between CD4 cell count and the risk of death was similar. Compared with 350-499 cells per μL, the adjusted rate ratio for CD4 count 500-699 cells per μL was 0·71 (95% CI 0·55-0·92), and for CD4 count of 700 cells per μL was 0·67 (95% CI 0·50-0·89). When the analysis was restricted to CD4 counts greater than 500 cells per μL, there was no signifi cant diff erence in the risk of death between the count categories (adjusted risk ratio for CD4 count 700 cells per μL or greater compared with 500-699 cells per μL: 0·84, 95% CI 0·65-1·10, p=0·22).
Discussion
Death rates in ART-naive people infected with HIV who have CD4 counts greater than 350 cells per μL tend to be higher than in the general population of industrialised countries. The increase in risk was substantial in injecting drug users and the heterosexual group but was small in men who have sex with men. This fi nding suggests that much of the raised risk in the former two risk groups probably results from confounding by socioeconomic and lifestyle factors, 11, 12 rather than being an eff ect of HIV infection itself. Consistent with this fi nding, an increased risk of death has been noted in the siblings of people with HIV infection compared with the siblings of a control population without HIV infection. 13 We also noted that a higher CD4 cell count was associated with a lower risk of death, even in this high range, a trend that has previously been seen in patients on ART. 2, 3 There seems to be a moderate HIV-related risk of death in antiretroviral-naive people with high CD4 cell counts. This risk increase applies despite the very low risk of AIDS-related diseases at this CD4 cell count. 14, 15 This fi nding is consistent with the hypothesis that in people with high CD4 cell counts, HIV causes increased mortality risk. [2] [3] [4] 16, 17 We identifi ed a higher risk of death in men than in women, which is consistent with the situation in the general population. When investigating the association between CD4 cell count and risk of death, in multivariate models fi tted to subsets of our data we were able to adjust for two potential confounding factors, hepatitis C co-infection and smoking history; the relation between death rate and CD4 cell count remained. We did not identify an association between plasma viral load and risk of death in the subset of patients for whom this information was available. This fi nding seems inconsistent with data suggesting an association between viral suppression and risk of non-AIDS-related diseases, 4 although here we are comparing people with various unsuppressed viral loads.
To our knowledge there have been no substantive studies restricted to ART-naive people; however, several studies have compared death rates in individuals infected with HIV, including those on ART, with those for the general population, matched for factors such as age and sex. [18] [19] [20] [21] Although all such studies have shown an excess risk of death in people with HIV infection, some successfully treated subgroups of patients have been identifi ed for whom death rates approach that of the general population. A study combining data from two French cohorts 18 found that the death rate in patients with CD4 counts greater than 500 cells per μL reached that of the general population by the sixth year after starting ART, whereas a study on a collaboration of HIV seroconverter cohorts 21 noted that, in the most recent period of follow-up (in which 73% of person-time was on ART), there was no excess mortality during the fi rst 5 years after seroconversion in patients infected sexually when compared with the general population.
Patients included in this analysis had been diagnosed earlier than most HIV-positive people in these settings. Of patients presenting with HIV infection from 1996 to 2006 at selected clinics in the UK, 39% had an initial CD4 count greater than 350 cells per μL. 22 Patients who are Viral load (log copies per mL)
Results were obtained from Poisson regression models: there were 419 deaths in 80 682 person-years. diagnosed earlier might diff er from patients diagnosed later in their attitudes towards health and access to health-care services. Although several included cohorts are linked to national death registers, a further limitation is that possible underascertainment of deaths might have resulted in underestimation of death rates. This possibility is supported by the slightly higher SMRs seen in the sensitivity analysis restricted to data from cohorts linked to national death registers. The decrease in risk of death over calendar time identifi ed in the multivariate model (table 3) could be due, at least partly, to a delay in the reporting of deaths.
Patients included in this study were under care at clinics linked to cohort studies and collaborations in Europe and North America. Results from this study might not be generalisable to all settings, either in clinics in these regions without research links, or in resourcelimited settings.
In conclusion, these data suggest that people with HIV who have not taken ART and have CD4 count greater than 350 cells per μL have a raised risk of death compared with the general uninfected population, although the increase seems to be small. Because ART might reduce the risk of death in such patients, these fi ndings support the need for continuing studies (such as the START trial 23 and further exploration of existing observational databases) of the risks and benefi ts of starting ART at CD4 counts greater than 350 cells per μL.
